Response to: 'Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'

被引：0
|
作者：
Homer, N. [1 ]
Grewal, D. S. [1 ]
Mirza, R. G. [1 ]
Lyon, A. T. [1 ]
Gill, M. K. [1 ]
机构：
[1] Northwestern Univ, Dept Ophthalmol, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
EYE | 2015年 / 29卷 / 12期
关键词：
D O I：
10.1038/eye.2015.191
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：1630 / 1631
页数：3
相关论文
共 50 条
  • [1] Response to: ‘Comment on Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’
    N Homer
    D S Grewal
    R G Mirza
    A T Lyon
    M K Gill
    Eye, 2015, 29 : 1630 - 1631
  • [2] Comment on ‘Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results’
    V P Dave
    Eye, 2015, 29 : 1630 - 1630
  • [3] Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results
    N Homer
    D S Grewal
    R G Mirza
    A T Lyon
    M K Gill
    Eye, 2015, 29 : 1152 - 1155
  • [4] Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results
    Homer, N.
    Grewal, D. S.
    Mirza, R. G.
    Lyon, A. T.
    Gill, M. K.
    EYE, 2015, 29 (09) : 1152 - 1155
  • [5] Transitioning Neovascular Age Related Macular Degeneration Patients to Aflibercept Following an Initial Treat And Extend Dosing Regimen: 18 Month Results
    Homer, Natalie
    Grewal, Dilraj Singh
    Lyon, Alice T.
    Mirza, Rukhsana
    Gill, Manjot
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2014, 55 (13)
  • [6] INTRAVITREAL AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH LIMITED RESPONSE TO RANIBIZUMAB A Treat-and-Extend Trial
    Hatz, Katja
    Prunte, Christian
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (06): : 1185 - 1192
  • [7] Treat-and-Extend Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration Efficacy and Macular Atrophy Development
    Matsumoto, Hidetaka
    Morimoto, Masahiro
    Mimura, Kensuke
    Ito, Arisa
    Akiyama, Hideo
    OPHTHALMOLOGY RETINA, 2018, 2 (05): : 462 - 468
  • [8] Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a "Treat-and-Extend" Regimen
    Traine, Peter G.
    Pfister, Isabel B.
    Zandi, Souska
    Spindler, Jan
    Garweg, Justus G.
    OPHTHALMOLOGY RETINA, 2019, 3 (05): : 393 - 399
  • [9] Efficacy of Intravitreal Aflibercept Treat-and-Extend Regimen Over 2 Years for Neovascular Age-Related Macular Degeneration: ARIES Study
    Souied, Eric H.
    Holz, Frank G.
    Hykin, Philip G.
    Midena, Edoardo
    Wolf, Sebastian
    Allmeier, Helmut
    Mitchell, Paul
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [10] Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen FLUID Study 24-Month Results
    Guymer, Robyn H.
    Markey, Caroline M.
    McAllister, Ian L.
    Gillies, Mark C.
    Hunyor, Alex P.
    Arnold, Jennifer J.
    OPHTHALMOLOGY, 2019, 126 (05) : 723 - 734
12345